Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda
Open Access
- 8 July 2008
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 5 (7) , e150
- https://doi.org/10.1371/journal.pmed.0050150
Abstract
Frank Cobelens and colleagues outline key research questions that need to be addressed to maximize the impact of programmatic management of drug-resistant tuberculosis.Keywords
This publication has 45 references indexed in Scilit:
- Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control.2006
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaPublished by Elsevier ,2006
- Multidrug-resistant Tuberculosis Management in Resource-limited SettingsEmerging Infectious Diseases, 2006
- Treatment of multidrug-resistant tuberculosis: evidence and controversies.2006
- Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsThe Lancet, 2006
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up studyEuropean Respiratory Journal, 2006
- Cost-Effectiveness of Treating Multidrug-Resistant TuberculosisPLoS Medicine, 2006
- Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.2006
- Drug-susceptibility testing in tuberculosis: methods and reliability of resultsEuropean Respiratory Journal, 2005